Semax
Semax
Semax is a nootropic peptide popular in cognitive-performance communities, but pharmacy access is still constrained by current FDA positioning.
Current status
Restricted
Cognitive-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Often paired with Selank in market conversations about future access changes.
Primary Use
Cognitive-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Nootropic peptide demand increased despite restrictive compounding treatment..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Semax status changes
State-specific notes
Florida
Availability changes quickly with pharmacy policy.